Atul Verma, MD, director of cardiology at McGill University Health Centre in Montreal, explained why the late-breaking PULSED-AF trial data on Medtronic’s pulsed-field ablation technology is so important for cardiologists. 

Browse a selection of photos from the American College of Cardiology's annual meeting in New Orleans. The pictures highlight key moments, new technologies and much more from the big show. 

Medtronic acquired the technology in a 2022 deal reportedly worth $925 million.

As this new ablation technique continues to gain momentum, researchers are hoping to learn as much as possible about any potential side effects. 

After its initial release was limited to certain customers, the new-look catheter is now available in four different sizes throughout the United States.

Although advanced imaging exams have proven benefits in defining disease severity, new data indicate that more sophisticated studies might not impact outcomes as much as previously thought. 

Paul Sorajja, MD, discusses the late-breaking TRILUMINATE pivotal trial at ACC.23 and how tricuspid TEER performed against the current standard of care using medical therapy.

Here are links to more information on every late-breaking presentation at ACC.23.